Pharma

Under settlement, Sackler family will pay state, local and Native American tribal governments, individual victims and othersSign up for the Breaking News US email to get newsletter alerts in your inboxA judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225m to the US justice department on Tuesday, clearing the way for the company to finalize a settlement of thousands of lawsuits it faces over its role in the opioid crisis.The penalty was agreed to in a 2020 pact to resolve federal civil and criminal investigations it was facing. If the judge signs off, other penalties will not be collected in return for Purdue settling the other lawsuits. Continue reading...

Proposal, a win for RFK Jr’s Maha movement, is a ‘first step’ toward tackling plastic pollution, advocates sayThe Environmental Protection Agency (EPA) proposed on Thursday to include microplastics and pharmaceuticals on a list of contaminants in drinking water for the first time, a step that could lead to new limits on those substances for water utilities.Lee Zeldin, the EPA administrator, said they are responding to Americans who have worried about plastics and pharmaceuticals in their drinking water. The gesture also aims to hand a win to health secretary Robert FKennedy Jr’s Maha movement, which for months has pressured Zeldin to further crack down on environmental contaminants. Continue reading...

Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medicationsGet our breaking news email, free app or daily news podcastAustralia will not cave in to pressure from pharmaceutical giants and the Trump administration by removing consumer price protections on common medications, the health minister, Mark Butler says.Donald Trump imposed a new 100% tariff on branded pharmaceuticals imported into the US overnight, Australian time, trying to force manufacturers to agree to drug-pricing deals or commit to making their products domestically. Continue reading...

• Eli Lilly announced the acquisition of Centessa Pharmaceuticals, a company developing treatments for excessive daytime sleepiness and neurological conditions, in a deal valued at up to $7.8 billion if certain conditions are met. • Centessa shares soared 44% on the news, while Lilly's stock rose 3.7%, helping offset broader market pressures from companies like McCormick. • The deal highlights Big Pharma's aggressive push into neuroscience amid rising demand for sleep disorder therapies, potentially boosting Lilly's pipeline.

• Express Scripts added CARDAMYST (etripamil) nasal spray to its commercial national formularies effective March 27, 2026, expanding access for commercially insured patients. • The FDA-approved self-administered spray converts acute paroxysmal supraventricular tachycardia (PSVT) episodes to sinus rhythm in adults. • This coverage decision makes the first-in-class treatment broadly affordable across the U.S., improving cardiovascular care options.

• The FDA issued an urgent safety alert on March 20, 2026, warning of counterfeit versions of semaglutide and tirzepatide circulating through unverified online retailers, with 47 adverse events reported including severe infections and allergic reactions. • Counterfeit products lack sterility assurance and may contain contaminated ingredients or incorrect dosing, posing serious health risks to consumers seeking weight loss or diabetes treatment. • The agency recommends patients obtain GLP-1 medications only through licensed pharmacies with valid prescriptions, emphasizing that legitimate suppliers require medical supervision.

As outbreak in Kent claims the lives of two young people, experts advise against rushing to get a vaccinePharmacies in England are reporting a surge in demand for meningitis vaccines after an outbreak in Kent claimed the lives of two young people and left others in hospital.However experts have advised against rushing to get a jab, stressing public health authorities are best placed to determine if vaccinations are required – and for whom. Continue reading...